Fiche publication
Date publication
septembre 2024
Journal
Immunotherapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GRANEL-BROCARD Florence
,
Dr NARDIN Charlée
Tous les auteurs :
Tzoumpa S, Villette B, Granel-Brocard F, Dutriaux C, Memmi A, Jeudy G, Tafani V, Saint-Jean M, Nardin C, Funck-Brentan E, Corre YL, Quereux G, Maubec E
Lien Pubmed
Résumé
Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.
Mots clés
groupe de Cancérologie Cutanée, immune checkpoint inhibitors, immune related adverse events, metastatic melanoma, symptomatic immuno-induced sinusitis
Référence
Immunotherapy. 2024 09 13;:1-9
